SEARCH

SEARCH BY CITATION

References

  • 1
    Lanier L: NK cell recognition. Annu Rev Immunol 2005; 23:225274
  • 2
    Alcami A, Koszinowski UH: Viral mechanisms of immune evasion. Immunol Today 2000; 21:447455
  • 3
    Algarra I, Garcia-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F: The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 2004; 53:904910
  • 4
    Long EO: Regulation of immune responses through inhibitory receptors. Annu Rev Immunol 1999; 17:875904
  • 5
    Barten R, Torkar M, Haude A, Trowsdale J, Wilson MJ: Divergent and convergent evolution of NK-cell receptors. Trends Immunol 2001; 22:5257
  • 6
    Yawata M, Yawata N, Draghi M, Partheniou F, Little A, Parham P: MHC class I-specific inhibitory receptors and their ligands structure diverse human NK cell repertoires towards a balance of missing-self response. Blood 2008; 112:23692380
  • 7
    Pascal V, Stulberg M, Anderson S: Regulation of class I major histocompatibility complex receptor expression in natural killer cells: one promoter is not enough. Immunol Rev 2006; 914:921
  • 8
    Bashirova A, Martin M, McVicar D, Carrington M: The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense. Annu Rev Genomics Hum Genet 2006; 7:277300
  • 9
    Makrigiannis AP, Pau AT, Schwartzberg PL, McVicar DW, Beck TW, Anderson SK: A BAC contig map of the Ly49 gene cluster in 129 mice reveals extensive differences in gene content relative to C57BL/6 mice. Genomics 2002; 79:437444
  • 10
    Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T: Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointenstinal epithelium. Proc Natl Acad Sci USA 1996; 93:1244512450
  • 11
    Karre K, Ljunggren HG, Piontek G, Kiessling R: Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986; 319:675678
  • 12
    Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, Yang L, French AR, Sunwoo JB, Lemieux S, Hansen TH, Yokoyama WM: Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005; 436:709713
  • 13
    Yokoyama W, Kim S: Licensing of natural killer cells by self-major histocompatibility complex class I. Immunol Rev 2006; 214:143154
  • 14
    Anfossi N, Andre P, Guia S, Falk C, Roetnynck S, Stewart C, Breso V, Frassati C, Reviron D, Middleton D, Romagne F, Ugolini S, Vivier E: Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006; 25:331342
  • 15
    Yu J, Heller G, Chewning J, Kim S, Yokoyama W, Hsu K: Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands. J Immunol 2007; 179:59775989
  • 16
    Kim S, Sunwoo J, Yang L, Choi T, Song Y, French A, Vlahiotis A, Piccirillo J, Cella M, Colonna M, Mohanakumar T, Hsu K, Dupont B, Yokoyama W: HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc Natl Acad Sci USA 2008; 105:30533058
  • 17
    Raulet D, Vance R: Self-tolerance of natural killer cells. Nat Rev Immunol 2006; 6:520531
  • 18
    Yawata M, Yawata N, Draghi M, Little A, Partheniou F, Parham P: Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med 2006; 203:633645
  • 19
    Johansson S, Johansson M, Rosmaraki E, Vahlne G, Mehr R, Salmon-Divon M, Lemonnier F, Karre K, Hoglund P: Natural killer cell education in mice with single or multiple major histocompatibility complex class I molecules. J Exp Med 2005; 201:11451155
  • 20
    Joncker N, Fernandez N, Treiner E, Vivier E, Raulet D: NK cell responsiveness is tuned commensurate with the number of inhibitory receptors for self-MHC class I: the rheostat model. J Immunol 2009; 182:45724580
  • 21
    Fernandez N, Treiner E, Vance R, Jamieson A, Lemieux S, Raulet D: A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood 2005; 105:44164423
  • 22
    Sun J, Lanier L: Cutting edge: viral infection breaks NK cell tolerance to “missing self”. J Immunol 2008; 181:74537457
  • 23
    Orr M, Murphy W, Lanier L: ‘Unlicensed’ natural killer cells dominate the response to cytomegalovirus infection. Nat Immunol 2010; 11:321327
  • 24
    Chewning J, Gudme C, Hsu K, Selvakumar A, Dupont B: KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro. J Immunol 2007; 179:854868
  • 25
    Fauriat C, Ivarsson M, Ljunggren H, Malmberg K, Michaelsson J: Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood 2010; 115:11661174
  • 26
    Blanc KL, Remberger M, Barrett J: Lymphocyte recovery is a major determinant of transplant outcome after myeloablative transplantation in patients with myeloid malignancies receiving matched unrelated stem cell allografts. Biol Blood Marrow Transplant 2009; 15:27 (Abstr).
  • 27
    Chang Y, Zhao X, Huang X: Effects of the NK cell recovery on outcomes of unmanipulated haploidentical blood and marrow transplantation for patients with hematologic malignancies. Biol Blood Marrow Transplant 2008; 14:323334
  • 28
    Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, Urbani E, Negrin RS, Martelli MF, Velardi A: Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999; 94:333339
  • 29
    Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295:20972100
  • 30
    Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, Stern M, Pende D, Perruccio K, Burchielli E, Topini F, Bianchi E, Aversa F, Martelli M, Velardi A: Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007; 110:433440
  • 31
    Yabe T, Matsuo K, Hirayasu K, Kashiwase K, Kawamura-Ishii S, Tanaka H, Ogawa A, Takanashi M, Satake M, Nakajima K, Tokunaga K, Inoko H, Saji H, Ogawa S, Juji T, Sasazuki T, Kodera Y, Morishima Y, Program JMD: Donor killer immunoglobulin-like receptor (KIR) genotype-patient cognate KIR ligand combination and antithymocyte globulin preadministration are critical factors in outcome of HLA-C-KIR ligand-mismatched T cell-replete unrelated bone marrow transplantation. Biol Blood Marrow Transplant 2008; 14:7587
  • 32
    Hsu K, Gooley T, Malkki M, Pinto-Agnello C, Dupont B, Bignon J, Bornhauser M, Christiansen F, Gratwohl A, Morishima Y, Oudshoorn M, Ringden O, Rood Jv, Petersdorf E; IHWG: KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant 2006; 12:828836
  • 33
    Hsu K, Keever-Taylor C, Wilton A, Pinto C, Heller G, Arkun K, O’Reilly R, Horowitz M, Dupont B: Improved outcome in allogeneic hematopoietic stem cell transplantation in acute myelogenous leukemia (AML) predicted by donor KIR genotype and recipient HLA genotype in T-cell depleted HLA-identical sibling transplants. Blood 2005; 105:48784884
  • 34
    Miller J, Cooley S, Parham P, Farag S, Verneris M, McQueen K, Guethlein L, Trachtenberg E, Haagenson M, Horowitz M, Klein J, Weisdorf D: Missing KIR-ligands is associated with less relapse and increased graft versus host disease (GVHD) following unrelated donor allogeneic HCT. Blood 2007; 109:50585061
  • 35
    Clausen J, Wolf D, Petzer A, Gunsilius E, Schumacher P, Kircher B, Gastl G, Nachbaur D: Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation. Clin Exp Immunol 2007; 148:520528
  • 36
    Sobecks R, Ball E, Maciejewski J, Rybicki L, Brown S, Kalaycio M, Pohlman B, Andresen S, Theil K, Dean R, Bolwell B: Survival of AML patients receiving HLA-matched sibling donor allogeneic bone marrow transplantation correlates with HLA-Cw ligand groups for killer immunoglobulin-like receptors. Bone Marrow Transplant 2007; 39:417424
  • 37
    Yu J, Venstrom J, Liu X, Pring J, Hasan R, O’Reilly R, Hsu K: Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T-cell depleted allogeneic hematopoietic cell transplantation. Blood 2009; 113:38753884
  • 38
    Chen C, Busson M, Rocha V, Appert M, Lepage V, Dulphy N, Haas P, Socie G, Toubert A, Charron D, Loiseau P: Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplant 2006; 38:437444
  • 39
    Bjorklund A, Schaffer M, Fauriat C, Ringden O, Remberger M, Mammarstedt C, Barrett A, Ljungman P, Ljunggren H, Malmberg K: NK cells expressing inhibitory KIR for non-self ligands remain tolerant in HLA-matched sibling stem cell transplantation. Blood 2010; 115:26862694
  • 40
    Leung W, Handgretinger R, Iyengar R, Turner V, Holladay M, Hale G: Inhibitory KIR-HLA receptor-ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma. Br J Cancer 2007; 97:539542
  • 41
    Venstrom J, Zheng J, Noor N, Danis K, Yeh A, Cheung I, Dupont B, O’Reilly R, Cheung N, Hsu K: KIR and HLA genotypes are associated with improved survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer Res 2009; 15:73307334
  • 42
    Verheyden S, Schots R, Duquet W, Demanet C: A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia 2005; 19:14461451
  • 43
    Pende D, Marcenaro S, Falco M, Martini S, Bernardo M, Mantagna D, Romeo E, Cognet C, Martinetti M, Maccario R, Mingari M, Vivier E, Moretta L, Locatelli F, Moretta A: Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 2009; 113:31193129
  • 44
    Cooley S, Trachtenberg E, Bergemann T, Saeteurn K, Klein J, Le C, Marsh S, Guethlein L, Parham P, Miller J, Weisdorf D: Donors with group B haplotypes improve relapse-free survival after unrelated hemaotpoietic transplantation for acute myeloid leukemia. Blood 2009; 113:726732
  • 45
    Venstrom J, Gooley T, Spellman S, Pring J, Malkki M, Dupont B, Petersdorf E, Hsu K: Donor activating KIR3DS1 is associated with decreased acute GvHD in unrelated allogeneic hematopoietic stem cell transplantation. Blood 2010; 115:31623165